Oppenheimer initiated coverage of Aclaris Therapeutics (ACRS) with an Outperform rating and $10 price target The firm sees a large commercial opportunity for the company’s immune-modulating portfolio assets. The price target reflects ATI-052 across atopic dermatitis and asthma, while Aclaris’ other assets have the potential to contribute substantially as they mature, the analyst tells investors in a research note. Opco anticipates a catalyst-rich year ahead for Aclaris as preclinical and clinical results are announced.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics: Advancing ATI-052 and Bosakitug Pipeline Underpins Buy Rating and $16 Price Target
- Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
- Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug
- Helus Pharma appoints Conwell as Chief People Officer
- Aclaris Therapeutics Raises $20 Million in Equity Financing